Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV

Overview of attention for article published in Pediatrics, November 1998

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source

facebook: 1 Facebook page
guideline: 5 clinical guideline sources

Readers on

mendeley: 53 Mendeley

So far, Altmetric has seen 7 Guidelines that reference this research output.

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Clinical guideline published by American Academy of Pediatrics (AAP) on 01 Aug 2014

The American Academy of Pediatrics (AAP) is committed to enhancing children's health and well-being through evidence-based guidelines, research, and advocacy. It offers resources for pediatricians, including educational materials, policy updates, and community engagement opportunities to support optimal care for children.

Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Clinical guideline published by American Academy of Pediatrics (AAP) on 01 Aug 2014

Guidelines for the use of palivizumab in infants and young children with congenital heart disease

Clinical guideline published by Japanese Society of Pediatric Cardiology and Cardiac Surgery (JSPCCS) on 05 Apr 2006

The Japanese Society of Pediatric Cardiology and Cardiac Surgery (JSPCCS) focuses on advancing pediatric cardiology and cardiac surgery through research, education, and collaboration. It hosts annual meetings and publishes relevant journals, fostering knowledge exchange among professionals in the field.

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

Clinical guideline published by The Food and Drug Administration (FDA) on 01 Dec 2003

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. FDA is responsible for, among many things, protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, food supply, cosmetics, and products that emit radiation.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity, including 3 additional posts.